Prader-Willi Syndrome Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Inversago, Saniona, GLWL Research, OptiNose, Helsinn, ConSynance, Neuren Pharma, Radius Health, Soleno

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 18+ key pharma and biotech companies are working on 18+ pipeline drugs in the Prader-Willi Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Prader-Willi Syndrome Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Prader-Willi Syndrome Therapeutics Market.

The report provides a detailed description of the Prader-Willi Syndrome drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Prader-Willi Syndrome Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/prader-willi-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Prader-Willi Syndrome Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Prader-Willi Syndrome therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Prader-Willi Syndrome treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Prader-Willi Syndrome drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Prader-Willi Syndrome treatment market.

Learn More about the Clinical and Commercial Development Activities in the Prader-Willi Syndrome Therapeutics Domain:
https://www.delveinsight.com/report-store/prader-willi-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Prader-Willi Syndrome Therapeutics Analysis
Currently, there is no cure for Prader-Willi Syndrome (PWS). The lives of individuals with Prader-Willi Syndrome can be improved with early diagnosis and careful management of symptoms, but more effective therapies are needed.

The treatment of Prader-Willi Syndrome is currently based on treating the symptoms of the disorder as they arise. Growth hormone deficiency is present in almost all children and many adults with Prader-Willi Syndrome. In multiple studies, human growth hormone (HGH) has been found to be beneficial for those with Prader-Willi syndrome.

In June of 2000, HGH was officially approved by the FDA in the United States for use in patients with Prader-Willi syndrome. HGH is effective not only in increasing height, but also in decreasing body fat, increasing muscle mass, improving weight distribution, increasing stamina, and increasing bone mineral density.

Some of the major approved GH therapies include Pfizer's GENOTROPIN (somatropin) along with other major brands such as NORDITROPIN (somatropin), OMNITROPE (somatropin [rDNA origin] injection) and a few others in the US to treat children with growth failure due to Prader-Willi syndrome.

There are approx. 18+ key companies developing therapies for Prader-Willi Syndrome. Currentley, Soleno Therapeutics is leading the therapeutics with its Prader-Willi Syndrome drug candidates in the most advanced stage of clinical development.

Prader-Willi Syndrome Companies in the Therapeutics Market Include:
• Soleno Therapeutics
• Levo Therapeutics
• Inversago Pharma
• Saniona
• LG Life Sciences
• GLWL Research
• OptiNose
• Larimar Therapeutics
• Helsinn
• ConSynance Therapeutics
• Neuren Pharmaceuticals
• Radius Health
• Rhythm
• Tonix Pharmaceuticals
And Many Others

Emerging and Marketed Prader-Willi Syndrome Therapies Covered in the Report Include:
• Diazoxide choline controlled release (DCCR): Soleno Therapeutics
• Intranasal carbetocin (LV-101): Levo Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Prader-Willi Syndrome Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Prader-Willi Syndrome Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Prader-Willi Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Prader-Willi Syndrome Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Prader-Willi Syndrome Current Treatment Patterns
4. Prader-Willi Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Prader-Willi Syndrome Late-Stage Products (Phase-III)
7. Prader-Willi Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prader-Willi Syndrome Discontinued Products
13. Prader-Willi Syndrome Product Profiles
14. Prader-Willi Syndrome Companies
15. Prader-Willi Syndrome Drugs
16. Dormant and Discontinued Products
17. Prader-Willi Syndrome Unmet Needs
18. Prader-Willi Syndrome Future Perspectives
19. Prader-Willi Syndrome Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.